Changing HaemophiliaTM

Changing Haemophilia is Novo Nordisk's commitment to address the unmet needs in haemophilia care, beyond medicine.
 

Haemophilia is a rare and serious disease

Haemophilia is a rare and serious disease affecting approx. 1 out of 10,000 people around the world. Many people with haemophilia are still undiagnosed or inadequately treated. Even when treated, people may suffer from chronic pain and limited mobility mainly due to bleeds in the joints, and if undertreated or not treated at all, risk dying at a young age.

Changing Haemophilia is Novo Nordisk's commitment to address the unmet needs in haemophilia care. We work towards a future where everyone with Haemophilia is diagnosed and can live a life with as few limitations as possible.
 

Our three Changing Haemophilia™ 
focus areas are:

 

 

Changing Haemophilia is Novo Nordisk's commitment to address the unmet needs in haemophilia care, beyond medicine

Haemophilia is a rare and serious disease

Haemophilia is a rare and serious disease affecting approx. 1 out of 10,000 people around the world. Many people with haemophilia are still undiagnosed or inadequately treated. Even when treated, people may suffer from chronic pain and limited mobility mainly due to bleeds in the joints, and if undertreated or not treated at all, risk dying at a young age.

Driving change in haemophilia 

Since Novo Nordisk was founded more than 90 years ago, we have been driving change to defeat chronic conditions. This includes three decades of improving lives of people with haemophilia through support to improved diagnosis, treatment and care.

Our key contribution 

Our key contribution is to discover and develop effective and safe medicines for people with haemophilia and other rare bleeding disorders. We offer a broad and innovative range of products and have a rich research/development pipeline to ensure we are in the forefront of finding the next generation of medicines.

Addressing unmet needs beyond medicine 

But to truly change haemophilia, we need to do more than supply the right medicines. With our Changing Haemophilia™ commitment we aim to address the unmet needs in haemophilia. Together with our community partners, we work to advocate for, and create better access to, diagnosis and multidisciplinary care. We aim for better joint health and mobility including a strong focus on well-being for people living with haemophilia.

We work towards a future where everyone with Haemophilia is diagnosed. and can live a life with as few limitations as possible.

Our three focus areas are:

•  Science. Find out more

•  Awareness and access to care. Find out more

•  Joint outcomes. Find out more


Novo Nordisk haemophilia research

Our key contribution

Our key contribution is to discover and develop effective and safe medicines for people with haemophilia and other rare bleeding disorders. We offer a broad and innovative range of products and have a rich research/development pipeline to ensure we are in the forefront of finding the next generation of medicines.

Haemophilia science


Changing Haemophilia, access to care, Mexico

Addressing unmet needs
beyond medicine

But to truly change haemophilia, we need to do more than supply the right medicines. Together with our community partners, we work to advocate for, and create better access to, diagnosis and multidisciplinary care. We aim for better joint health and mobility including a strong focus on well-being for people living with haemophilia. 


Novo Nordisk Haemophilia Foundation

Novo Nordisk Haemophilia Foundation

The Novo Nordisk Haemophilia Foundation (NNHF) approach is to partner with local and international community members to make change becoming a reality. The NNHF work in favour of people with haemophilia and allied bleeding disorders improving their access to care, treatment and quality of life. Together we focus on supporting the estimated 75% of the global patient population living in the developing world where still many lack proper diagnosis and adequate care.

Novo Nordisk Haemophilia Foundation

This page is intended for members of the UK public
UK/WB/1116/0064 November 2016


Novo Nordisk Changing Haemophilia